microsoft office windows 7 student discount best price ms windows 7 professional word 2007 best buy buy microsoft office enterprise 2007 buy office 2010 student buy visio 2003 buy adobe premiere 6.5 buy office 2013 standard adobe premiere elements 8 best price buy paint shop pro x2 uk buy resolume avenue cheap parallels 5 forefront threat management gateway cost discount microsoft office 2007 software best price adobe acrobat professional 9 for mac best price painter x buying microsoft money 2010 best buy office 2008 for mac buy windows 7 aus purchase microsoft office for students buy windows server 2008 standard buy capture nx2 full version autocad lt 2009 price best buy chief architect cheap ilife 11 buy adobe flash cs4 professional software buy paperport where can i buy windows 7 starter edition buy punch home design suite windows 7 discount edu

Prevalence and Treatment Management of Oropharyngeal Candidiasis in Cancer Patients: Results of the French Candidoscope Study

Tue, Sep 20, 2011

Oral Cancer News



The aim of this pharmaco-epidemiological study was to evaluate the prevalence of oropharyngeal candidiasis (OPC) in cancer patients treated with chemotherapy and/or radiotherapy.

Methods and Materials

Signs and symptoms of OPC were noted for all patients. Antifungal therapeutic management was recorded in OPC patients. Patients receiving local antifungal treatments were monitored until the end of treatment.


Enrolled in the study were 2,042 patients with solid tumor and/or lymphoma treated with chemotherapy and/or another systemic cancer treatment and/or radiotherapy. The overall prevalence of OPC was 9.6% (95% confidence interval, 8.4%–11.0%] in this population. It was most frequent in patients treated with combined chemoradiotherapy (22.0%) or with more than two cytotoxic agents (16.9%). Local antifungal treatments were prescribed in 75.0% of OPC patients as recommended by guidelines. The compliance to treatment was higher in patients receiving once-daily miconazole mucoadhesive buccal tablet (MBT; 88.2%) than in those treated with several daily mouthwashes of amphotericin B (40%) or nystatin (18.8%).


OPC prevalence in treated cancer patients was high. Local treatments were usually prescribed as per guidelines. Compliance to local treatments was better with once-daily drugs.

This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Print Friendly
Be Sociable, Share!
, , , , ,

Leave a Reply

You must be logged in to post a comment.